Zealand Pharma's stock fell 22% after a late-stage trial of Boehringer Ingelheim’s weight-loss drug survodutide revealed about 20% of users stopped treatment due to gastrointestinal side effects, compared to under 3% on placebo. This low tolerability could limit the drug's use in the obesity market, according to Goldman Sachs analysts. The results raise concerns about the drug's commercial potential despite its efficacy. Investors reacted negatively, reflecting uncertainty about the drug's future adoption.
Royal Unibrew initiated a share buy-back program in February 2026, which was increased from DKK 400 million to DKK 700 million in April 2026. The program is set to run until August 14, 2026, with total repurchases not exceeding DKK 700 million. As of...
Bavarian Nordic A/S has repurchased 50,169 of its own shares at an average price of DKK 182.35 since starting its share buyback program on June 2, 2026. The program allows the company to buy back shares up to a total value of DKK 150 million by July ...
Bavarian Nordic A/S has repurchased 50,169 shares at an average price of DKK 182.35, totaling DKK 9.15 million, as part of its share buy-back program running from June 2 to July 10, 2026. This program allows the company to buy back shares up to DKK 1...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early June 2026, the bank has repurchased 1,160,124 shares at an average price of DKK 904.31, totaling about DKK...
Jyske Bank has continued its share repurchase program, acquiring shares valued at over DKK 1 billion since February 2026. The bank has bought a total of 1,160,124 treasury shares, representing 1.99% of its share capital, with transactions conducted u...
